Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- World journal of gastroenterology
- Publicado em
- 28 jan 2024
- Citações
- 11
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Hepatic arterial infusion chemotherapy with anti-angiogenesis agents and immune checkpoint inhibitors for unresectable hepatocellular carcinoma and meta-analysis
Yu-Zhe Cao, Guang-Lei Zheng, Tian-Qi Zhang, Hong-Yan Shao, Jia-Yu Pan, Zi-Lin Huang, Meng-Xuan Zuo
Descritores MeSH
- Antineoplastic Agents
- Carcinoma, Hepatocellular
- Liver Neoplasms
- Infusions, Intra-Arterial
- Retrospective Studies
- Randomized Controlled Trials as Topic
- Treatment Outcome
- Angiogenesis Inhibitors
- B7-H1 Antigen
- Sorafenib
Veja também
Estudos relacionados
- PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis
- Is PD-1/PD-L1 inhibitor plus bevacizumab superior to sorafenib as first-line treatment for advanced hepatocellular carcinoma? A pooled analysis of four phase 3 RCTs
- Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma
- Evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis